The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (September 2019)
The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States. Download here
The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (June 2019)
The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States. Download here
The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (March 2019)
The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition*, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States. Download here
The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (April 2017)
The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people with MS in the United States. Download here
The use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence (March 2017)
The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people with MS in the United States. Download here
MS Coalition Brochure (January 2012)
The Multiple Sclerosis Coalition (MSC) was founded in 2005 by three independent multiple sclerosis (MS) organizations in an effort to work together to benefit individuals with MS. Since that time, the MSC has grown to nine member organizations, all of whom provide critical MS programs and services. Download here
Today we have published updated global advice for people with MS on the COVID-19 mRNA vaccines (Pfizer-BioNTech & Moderna). This advice has been developed by MS clinicians and research experts from across the global MS movement. #MSCOVID19
Participate in this interactive demonstration of dance therapy for MS. It's adapted for people of all abilities. Join us for this free conference on Friday, Jan 15 at 2:00 p.m. Eastern. Pre-register at https://buff.ly/2XvgvYZ
A Relative Afferent Pupillary Defect (RAPD) or Marcus Gunn pupil is a sign of damage to the optic nerve, which can be a symptom multiple sclerosis (MS).